{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:02:09Z","timestamp":1774627329685,"version":"3.50.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["22K12887"],"award-info":[{"award-number":["22K12887"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00277-023-05266-7","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:02:28Z","timestamp":1683871348000},"page":"1645-1656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6143-7906","authenticated-orcid":false,"given":"Satoshi","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"5266_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.15735","volume":"185","author":"QA Hill","year":"2019","unstructured":"Hill QA, Grainger JD, Thachil J, Provan D, Evans G, Garg M, Bradbury C, Bagot C, Kanis JA, Compston JE, British Society of Haematology in conjunction with the UK ITP forum (2019) The prevention of glucocorticoid- induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. Br J Haematol 185:410\u2013417. https:\/\/doi.org\/10.1111\/bjh.15735","journal-title":"Br J Haematol"},{"key":"5266_CR2","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, Gonz\u00e1lez-L\u00f3pez TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3:3780\u20133817. https:\/\/doi.org\/10.1182\/bloodadvances.2019000812","journal-title":"Blood Adv"},{"key":"5266_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319\u20131328. https:\/\/doi.org\/10.1007\/s00198-007-0394-0","journal-title":"Osteoporos Int"},{"key":"5266_CR4","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, K\u00fchne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK (2019) American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3:3829\u20133866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"key":"5266_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4081\/reumatismo.2017.922","volume":"69","author":"M Rossini","year":"2017","unstructured":"Rossini M, Viapiana O, Vitiello M, Malavolta N, La Montagna G, Maddali Bongi S, Di Munno O, Nuti R, Manzini CU, Ferri C, Bogliolo L, Mathieu A, Cantatore F, Del Puente A, Muratore M, Grassi W, Frediani B, Saviola G, Delvino P, Mirone L, Ferraccioli G, Tripi G, Piazza I, Gatti D (2017) Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo 69:30\u201339. https:\/\/doi.org\/10.4081\/reumatismo.2017.922","journal-title":"Reumatismo"},{"key":"5266_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777\u2013787. https:\/\/doi.org\/10.1007\/s001980200108","journal-title":"Osteoporos Int"},{"key":"5266_CR7","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521\u20131537. https:\/\/doi.org\/10.1002\/art.40137","journal-title":"Arthritis Rheumatol"},{"key":"5266_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 4:368\u2013381. https:\/\/doi.org\/10.1007\/BF01622200","journal-title":"WHO Study Group Osteoporos Int"},{"key":"5266_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1076029609350889","volume":"16","author":"S Nomura","year":"2010","unstructured":"Nomura S, Kurata Y, Tomiyama Y, Takubo T, Hasegawa M, Saigo K, Nishikawa M, Higasa S, Maeda Y, Hayashi K (2010) Effects of bisphosphonate administration on the bone mass in immune thrombocytopenic purpura patients under treatment with steroids. Clin Appl Thromb Hemost 16:622\u2013627. https:\/\/doi.org\/10.1177\/1076029609350889","journal-title":"Clin Appl Thromb Hemost"},{"key":"5266_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.schres.2022.12.008","volume":"14","author":"S Yamasaki","year":"2022","unstructured":"Yamasaki S, Kamezaki K, Ito Y, Horiuchi T (2022) Bisphosphonate use for glucocorticoid-induced osteoporosis in elderly patients with immune thrombocytopenia receiving prolonged steroid therapy: a single institute retrospective Study. Hematol Rep 14:276\u2013285. https:\/\/doi.org\/10.1016\/j.schres.2022.12.008","journal-title":"Hematol Rep"},{"key":"5266_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","volume":"94","author":"H Frederiksen","year":"1999","unstructured":"Frederiksen H, Schmidt K (1999) The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94:909\u2013913","journal-title":"Blood"},{"key":"5266_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0039-1683416","volume":"39","author":"R Kohli","year":"2019","unstructured":"Kohli R, Chaturvedi S (2019) Epidemiology and clinical manifestations of immune thrombocytopenia. Hamostaseologie 39:238\u2013249. https:\/\/doi.org\/10.1055\/s-0039-1683416","journal-title":"Hamostaseologie"},{"key":"5266_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jth.12813","volume":"13","author":"C Neunert","year":"2015","unstructured":"Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, Kelton JG, Arnold DM (2015) Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 13:457\u2013467. https:\/\/doi.org\/10.1111\/jth.12813","journal-title":"J Thromb Haemost"},{"key":"5266_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0140-6736(02)07275-6","volume":"359","author":"B Godeau","year":"2002","unstructured":"Godeau B, Chevret S, Varet B, Lefr\u00e8re F, Zini JM, Bassompierre F, Ch\u00e8ze S, Legouffe E, Hulin C, Grange MJ, Fain O, Bierling P, French ATIP Study Group (2002) Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 359:23\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(02)07275-6","journal-title":"Lancet"},{"key":"5266_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1182\/blood.V79.4.942.942","volume":"79","author":"H Mizutani","year":"1992","unstructured":"Mizutani H, Furubayashi T, Imai Y, Kashiwagi H, Honda S, Take H, Kurata Y, Yonezawa T, Tarui S, Ikehara S (1992) Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW x BXSB) F1. Blood 79:942\u2013947","journal-title":"Blood"},{"key":"5266_CR16","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","volume":"3","author":"S Mithoowani","year":"2016","unstructured":"Mithoowani S, Gregory-Miller K, Goy J, Miller MC, Wang G, Noroozi N, Kelton JG, Arnold DM (2016) High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 3:e489\u2013e496. https:\/\/doi.org\/10.1016\/S2352-3026(16)30109-0","journal-title":"Lancet Haematol"},{"issue":"1","key":"5266_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood.V77.1.31.31","volume":"77","author":"S Cortelazzo","year":"1991","unstructured":"Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T (1991) High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 77(1):31\u201333","journal-title":"Blood"},{"key":"5266_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-0609.2009.01265.x","volume":"83","author":"JA Guidry","year":"2009","unstructured":"Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR (2009) Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol 83:175\u2013182. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01265.x","journal-title":"Eur J Haematol"},{"key":"5266_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1600-0609.2009.01322.x","volume":"83","author":"JA Guidry","year":"2009","unstructured":"Guidry JA, Watson S, George JN, Vesely SK, Terrell DR (2009) Addendum to corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient perspectives. Eur J Haematol 83:497\u2013498. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01322.x","journal-title":"Eur J Haematol"},{"key":"5266_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1055\/s-0034-1544001","volume":"41","author":"A Cuker","year":"2015","unstructured":"Cuker A, Prak ET, Cines DB (2015) Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost 41:395\u2013404. https:\/\/doi.org\/10.1055\/s-0034-1544001","journal-title":"Semin Thromb Hemost"},{"key":"5266_CR21","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2100596","volume":"385","author":"CA Bradbury","year":"2021","unstructured":"Bradbury CA, Pell J, Hill Q, Bagot C, Cooper N, Ingram J, Breheny K, Kandiyali R, Rayment R, Evans G, Talks K, Thomas I, Greenwood R (2021) Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med 385:885\u2013895. https:\/\/doi.org\/10.1056\/NEJMoa2100596","journal-title":"N Engl J Med"},{"key":"5266_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMe2110953","volume":"385","author":"PHB Bolton-Maggs","year":"2021","unstructured":"Bolton-Maggs PHB, George JN (2021) Immune thrombocytopenia treatment. N Engl J Med 385:948\u2013950. https:\/\/doi.org\/10.1056\/NEJMe2110953","journal-title":"N Engl J Med"},{"key":"5266_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/ajh.25301","volume":"94","author":"LC Bylsma","year":"2019","unstructured":"Bylsma LC, Fryzek JP, Cetin K, Callaghan F, Bezold C, Mehta B, Wasser JS (2019) Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol 94:118\u2013132. https:\/\/doi.org\/10.1002\/ajh.25301","journal-title":"Am J Hematol"},{"key":"5266_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/ejh.12146","volume":"91","author":"JR Gonzalez-Porras","year":"2013","unstructured":"Gonzalez-Porras JR, Escalante F, Pardal E, Sierra M, Garcia-Frade LJ, Redondo S, Arefi M, Aguilar C, Ortega F, de Cabo E, Fisac RM, Sanz O, Esteban C, Alberca I, Sanchez-Barba M, Santos MT, Fernandez A, Gonzalez-Lopez TJ, representing the Grupo de Trombosis y Hemostasia de Castilla y Le\u00f3n (2013) Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 91:236\u2013241. https:\/\/doi.org\/10.1111\/ejh.12146","journal-title":"Eur J Haematol"},{"key":"5266_CR25","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","volume":"104","author":"K Kojouri","year":"2004","unstructured":"Kojouri K, Vesely SK, Terrell DR, George JN (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104:2623\u20132634. https:\/\/doi.org\/10.1182\/blood-2004-03-1168","journal-title":"Blood"},{"key":"5266_CR26","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1046\/j.1365-2141.2001.02615.x","volume":"112","author":"F Fabris","year":"2001","unstructured":"Fabris F, Tassan T, Ramon R, Carraro G, Randi ML, Luzzatto G, Moschino P, Girolami A (2001) Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura. Br J Haematol 112:637\u2013640. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02615.x","journal-title":"Br J Haematol"},{"key":"5266_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140\u2013174. https:\/\/doi.org\/10.1159\/000082102","journal-title":"Curr Dir Autoimmun"},{"key":"5266_CR28","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","volume":"2","author":"S Chugh","year":"2015","unstructured":"Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, Heddle NM, Kelton JG, Arnold DM (2015) Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2:e75-81. https:\/\/doi.org\/10.1016\/S2352-3026(15)00003-4","journal-title":"Lancet Haematol"},{"key":"5266_CR29","doi-asserted-by":"publisher","first-page":"16531661","DOI":"10.1016\/S0140-6736(14)61495-1","volume":"385","author":"W Ghanima","year":"2015","unstructured":"Ghanima W, Khelif A, Waage A, Michel M, Tj\u00f8nnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA, RITP study group (2015) Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 385:16531661. https:\/\/doi.org\/10.1016\/S0140-6736(14)61495-1","journal-title":"Lancet"},{"key":"5266_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-2141.2012.09169.x","volume":"158","author":"S Auger","year":"2012","unstructured":"Auger S, Duny Y, Rossi JF, Quittet P (2012) Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 158:386\u2013398. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09169.x","journal-title":"Br J Haematol"},{"key":"5266_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","volume":"146","author":"DM Arnold","year":"2007","unstructured":"Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25\u201333","journal-title":"Ann Intern Med"},{"key":"5266_CR32","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","volume":"119","author":"VL Patel","year":"2012","unstructured":"Patel VL, Mah\u00e9vas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser M, Cooper N, Bussel JB (2012) Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 119:5989\u20135995. https:\/\/doi.org\/10.1182\/blood-2011-11-393975","journal-title":"Blood"},{"key":"5266_CR33","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","volume":"122","author":"I Nazi","year":"2013","unstructured":"Nazi I, Kelton JG, Larch\u00e9 M, Snider DP, Heddle NM, Crowther MA, Cook RJ, Tinmouth AT, Mangel J, Arnold DM (2013) The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 122:1946\u20131953. https:\/\/doi.org\/10.1182\/blood-2013-04-494096","journal-title":"Blood"},{"key":"5266_CR34","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","volume":"124","author":"M Khellaf","year":"2014","unstructured":"Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, Graveleau J, Slama B, Audia S, Ebbo M, Le Guenno G, Cliquennois M, Salles G, Bonmati C, Teillet F, Galicier L, Hot A, Lambotte O, Lefr\u00e8re F, Sacko S, Kengue DK, Bierling P, Roudot-Thoraval F, Michel M, Godeau B (2014) Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 124:3228\u20133236. https:\/\/doi.org\/10.1182\/blood-2014-06-582346","journal-title":"Blood"},{"key":"5266_CR35","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/bjh.17813","volume":"195","author":"E Crickx","year":"2021","unstructured":"Crickx E, Moulis G, Ebbo M, Terriou L, Briantais A, Languille L, Limal N, Guillet S, Michel M, Mahevas M, Godeau B (2021) Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia. Br J Haematol 195:703\u2013705. https:\/\/doi.org\/10.1111\/bjh.17813","journal-title":"Br J Haematol"},{"key":"5266_CR36","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/bloodadvances.2021006379","volume":"6","author":"C Visser","year":"2022","unstructured":"Visser C, Swinkels M, van Werkhoven ED, Croles FN, Noordzij-Nooteboom HS, Eefting M, Last-Koopmans SM, Idink C, Westerweel PE, Santbergen B, Jobse PA, Baboe F, RECOVAC-IR Consortium, Te Boekhorst PAW, Leebeek FWG, Levin MD, Kruip MJHA, Jansen AJG (2022) COVID-19 vaccination in patients with immune thrombocytopenia. Blood Adv 6:1637\u20131644","journal-title":"Blood Adv"},{"key":"5266_CR37","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834\u20134840. https:\/\/doi.org\/10.1182\/blood-2008-10-186999","journal-title":"Blood"},{"key":"5266_CR38","doi-asserted-by":"publisher","unstructured":"Zeng Y, Duan X, Xu J, Ni X (2011) TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev CD008235. https:\/\/doi.org\/10.1002\/14651858.CD008235","DOI":"10.1002\/14651858.CD008235"},{"key":"5266_CR39","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1002\/ajh.23900","volume":"90","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Pascual C, \u00c1lvarez-Rom\u00e1n MT, Fern\u00e1ndez-Fuertes F, S\u00e1nchez-Gonz\u00e1lez B, Caparr\u00f3s I, Jarque I, Mingot-Castellano ME, Hern\u00e1ndez-Rivas JA, Mart\u00edn-Salces M, Sol\u00e1n L, Beneit P, Jim\u00e9nez R, Bernat S, Andrade MM, Cort\u00e9s M, Cortti MJ, P\u00e9rez-Crespo S, G\u00f3mez-N\u00fa\u00f1ez M, Olivera PE, P\u00e9rez-Rus G, Mart\u00ednez-Robles V, Alonso R, Fern\u00e1ndez-Rodr\u00edguez A, Arratibel MC, Perera M, Fern\u00e1ndez-Mi\u00f1ano C, Fuertes-Palacio MA, V\u00e1zquez-Paganini JA, Gutierrez-Jomarr\u00f3n I, Valcarce I, de Cabo E, Sainz A, Fisac R, Aguilar C, Paz Mart\u00ednez-Badas M, Pe\u00f1arrubia MJ, Calbacho M, de Cos C, Gonz\u00e1lez-Silva M, Coria E, Alonso A, Casaus A, Lua\u00f1a A, Gal\u00e1n P, Fern\u00e1ndez-Canal C, Garcia-Frade J, Gonz\u00e1lez-Porras JR (2015) Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 90:E40\u2013E43. https:\/\/doi.org\/10.1002\/ajh.23900","journal-title":"Am J Hematol"},{"key":"5266_CR40","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","volume":"113","author":"JB Bussel","year":"2009","unstructured":"Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113:2161\u20132171. https:\/\/doi.org\/10.1182\/blood-2008-04-150078","journal-title":"Blood"},{"key":"5266_CR41","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/rth2.12423","volume":"4","author":"LS Lal","year":"2020","unstructured":"Lal LS, Said Q, Andrade K, Cuker A (2020) Second-line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records. Res Pract Thromb Haemost 4:1131\u20131140. https:\/\/doi.org\/10.1002\/rth2.12423","journal-title":"Res Pract Thromb Haemost"},{"key":"5266_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ajh.21109","volume":"83","author":"F Rodeghiero","year":"2008","unstructured":"Rodeghiero F, Ruggeri M (2008) Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol 83:91. https:\/\/doi.org\/10.1002\/ajh.21109","journal-title":"Am J Hematol"},{"key":"5266_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/MOH.0b013e3282c8ca50","volume":"14","author":"N Cooper","year":"2007","unstructured":"Cooper N, Evangelista ML, Amadori S, Stasi R (2007) Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol 14:642\u2013646. https:\/\/doi.org\/10.1097\/MOH.0b013e3282c8ca50","journal-title":"Curr Opin Hematol"},{"key":"5266_CR44","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ajh.24011","volume":"90","author":"RK Brynes","year":"2015","unstructured":"Brynes RK, Orazi A, Theodore D, Burgess P, Bailey CK, Thein MM, Bakshi KK (2015) Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study. Am J Hematol 90:598\u2013601. https:\/\/doi.org\/10.1002\/ajh.24011","journal-title":"Am J Hematol"},{"key":"5266_CR45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-120-3-199402010-00005","volume":"120","author":"PM Zelissen","year":"1994","unstructured":"Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA (1994) Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120:207\u2013210. https:\/\/doi.org\/10.7326\/0003-4819-120-3-199402010-00005","journal-title":"Ann Intern Med"},{"key":"5266_CR46","doi-asserted-by":"publisher","first-page":"CD000952","DOI":"10.1002\/14651858.CD000952","volume":"1998","author":"J Homik","year":"2000","unstructured":"Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P (2000) Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 1998:CD000952. https:\/\/doi.org\/10.1002\/14651858.CD000952","journal-title":"Cochrane Database Syst Rev"},{"key":"5266_CR47","doi-asserted-by":"publisher","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","volume":"125","author":"LM Buckley","year":"1996","unstructured":"Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125:961\u2013968. https:\/\/doi.org\/10.7326\/0003-4819-125-12-199612150-00004","journal-title":"Ann Intern Med"},{"key":"5266_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","volume":"16","author":"Y Boutsen","year":"2001","unstructured":"Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16:104\u2013112. https:\/\/doi.org\/10.1359\/jbmr.2001.16.1.104","journal-title":"J Bone Miner Res"},{"key":"5266_CR49","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1056\/NEJM199306173282404","volume":"328","author":"P Sambrook","year":"1993","unstructured":"Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747\u20131752. https:\/\/doi.org\/10.1056\/NEJM199306173282404","journal-title":"N Engl J Med"},{"key":"5266_CR50","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309\u20132318. https:\/\/doi.org\/10.1002\/1529-0131(199911)42:11%3c2309::AID-ANR8%3e3.0.CO;2-K","journal-title":"Arthritis Rheum"},{"key":"5266_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292\u2013299. https:\/\/doi.org\/10.1056\/NEJM199807303390502","journal-title":"N Engl J Med"},{"key":"5266_CR52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00198-003-1570-5","volume":"15","author":"F Richy","year":"2004","unstructured":"Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301\u2013310. https:\/\/doi.org\/10.1007\/s00198-003-1570-5","journal-title":"Osteoporos Int"},{"key":"5266_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.7326\/0003-4819-112-5-352","volume":"112","author":"BP Lukert","year":"1990","unstructured":"Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352\u2013364. https:\/\/doi.org\/10.7326\/0003-4819-112-5-352","journal-title":"Ann Intern Med"},{"key":"5266_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.afos.2020.02.001","volume":"6","author":"H Okamoto","year":"2020","unstructured":"Okamoto H, Shibazaki N, Yoshimura T, Uzawa T, Sugimoto T (2020) Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis. Osteoporos Sarcopenia 6:15\u201319. https:\/\/doi.org\/10.1016\/j.afos.2020.02.001","journal-title":"Osteoporos Sarcopenia"},{"key":"5266_CR55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0026-0495(83)90221-4","volume":"32","author":"Y Suzuki","year":"1983","unstructured":"Suzuki Y, Ichikawa Y, Saito E, Homma M (1983) Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32:151\u2013156. https:\/\/doi.org\/10.1016\/0026-0495(83)90221-4","journal-title":"Metabolism"},{"key":"5266_CR56","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1359\/jbmr.2003.18.5.919","volume":"18","author":"PN Sambrook","year":"2003","unstructured":"Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Re 18:919\u2013924. https:\/\/doi.org\/10.1359\/jbmr.2003.18.5.919","journal-title":"J Bone Miner Re"},{"key":"5266_CR57","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1056\/NEJMoa053569","volume":"355","author":"RN de Nijs","year":"2006","unstructured":"de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW, Investigators STOP (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675\u2013684. https:\/\/doi.org\/10.1056\/NEJMoa053569","journal-title":"N Engl J Med"},{"key":"5266_CR58","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809\u2013816. https:\/\/doi.org\/10.1007\/s00198-010-1524-7","journal-title":"Osteoporos Int"},{"key":"5266_CR59","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Mar\u00edn F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u20132039. https:\/\/doi.org\/10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"key":"5266_CR60","doi-asserted-by":"publisher","first-page":"CD001347","DOI":"10.1002\/14651858.CD001347.pub2","volume":"10","author":"CS Allen","year":"2016","unstructured":"Allen CS, Yeung JH, Vandermeer B, Homik J (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 10:CD001347. https:\/\/doi.org\/10.1002\/14651858.CD001347.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5266_CR61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","volume":"148","author":"C MacLean","year":"2008","unstructured":"MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197\u2013213. https:\/\/doi.org\/10.7326\/0003-4819-148-3-200802050-00198","journal-title":"Ann Intern Med"},{"key":"5266_CR62","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/archinte.1996.00440100065008","volume":"156","author":"IR Reid","year":"1996","unstructured":"Reid IR, Wattie DJ, Evans MC, Stapleton JP (1996) Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156:1173\u20131177 (PMID: 8639011)","journal-title":"Arch Intern Med"},{"key":"5266_CR63","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1210\/jc.2002-021827","volume":"88","author":"BA Crawford","year":"2003","unstructured":"Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167\u20133176. https:\/\/doi.org\/10.1210\/jc.2002-021827","journal-title":"J Clin Endocrinol Metab"},{"key":"5266_CR64","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1172\/JCI6800","volume":"104","author":"LI Plotkin","year":"1999","unstructured":"Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363\u20131374. https:\/\/doi.org\/10.1172\/JCI6800","journal-title":"J Clin Invest"},{"key":"5266_CR65","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1172\/JCI14538","volume":"109","author":"RS Weinstein","year":"2002","unstructured":"Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC (2002) Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041\u20131048. https:\/\/doi.org\/10.1172\/JCI14538","journal-title":"J Clin Invest"},{"key":"5266_CR66","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202\u2013211. https:\/\/doi.org\/10.1002\/1529-0131(200101)44:1%3c202::AID-ANR27%3e3.0.CO;2-W","journal-title":"Arthritis Rheum"},{"key":"5266_CR67","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3899\/jrheum.081207","volume":"36","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705\u20131714. https:\/\/doi.org\/10.3899\/jrheum.081207","journal-title":"J Rheumatol"},{"key":"5266_CR68","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2017.8040","volume":"318","author":"KF Axelsson","year":"2017","unstructured":"Axelsson KF, Nilsson AG, Wedel H, Lundh D, Lorentzon M (2017) Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 318:146\u2013155. https:\/\/doi.org\/10.1001\/jama.2017.8040","journal-title":"JAMA"},{"key":"5266_CR69","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006\u20131013. https:\/\/doi.org\/10.1359\/jbmr.2000.15.6.1006","journal-title":"J Bone Miner Res"},{"key":"5266_CR70","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s001980070122","volume":"11","author":"R Eastell","year":"2000","unstructured":"Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RG (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11:331\u2013337. https:\/\/doi.org\/10.1007\/s001980070122","journal-title":"Osteoporos Int"},{"key":"5266_CR71","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN, HORIZON investigators, (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253\u20131263. https:\/\/doi.org\/10.1016\/S0140-6736(09)60250-6","journal-title":"Lancet"},{"key":"5266_CR72","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1210\/jcem.80.10.7559865","volume":"80","author":"AR Hermus","year":"1995","unstructured":"Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing\u2019s syndrome. J Clin Endocrinol Metab 80:2859\u20132565. https:\/\/doi.org\/10.1210\/jcem.80.10.7559865","journal-title":"J Clin Endocrinol Metab"},{"key":"5266_CR73","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N, National Osteoporosis Guideline Group (NOGG) (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43. https:\/\/doi.org\/10.1007\/s11657-017-0324-5","journal-title":"Arch Osteoporos"},{"key":"5266_CR74","first-page":"1309","volume":"24","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y (2014) Glucocorticoid and Bone. Updated Japanese guidelines for the management of glucocorticoid-induced osteoporosis. Clin Calcium 24:1309\u20131318","journal-title":"Clin Calcium"},{"key":"5266_CR75","unstructured":"2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Published online September 14, 2022. https:\/\/www.rheumatology.org\/Portals\/0\/Files\/Prevention-Treatment-GIOP-Guideline-Summary.pdf. Accessed 21 Sept 2022"},{"key":"5266_CR76","doi-asserted-by":"publisher","first-page":"961471","DOI":"10.3389\/fendo.2022.961471","volume":"13","author":"B Jiang","year":"2022","unstructured":"Jiang B, Feng C, Li C, Tu C (2022) A bibliometric and visualization analysis of\u00a0glucocorticoid-induced\u00a0osteoporosis\u00a0research from 2012 to 2021. Front Endocrinol (Lausanne) 13:961471. https:\/\/doi.org\/10.3389\/fendo.2022.961471","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5266_CR77","doi-asserted-by":"publisher","first-page":"14967","DOI":"10.1038\/s41598-022-19079-7","volume":"12","author":"T Morikawa","year":"2022","unstructured":"Morikawa T, Sakuma M, Nakamura T, Sonoyama T, Matsumoto C, Takeuchi J, Ohta Y, Kosaka S, Morimoto T (2022) Effectiveness of a computerized clinical decision support system for prevention of glucocorticoid-induced osteoporosis. Sci Rep 12:14967. https:\/\/doi.org\/10.1038\/s41598-022-19079-7","journal-title":"Sci Rep"},{"key":"5266_CR78","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00774-022-01323-9","volume":"40","author":"M Takahata","year":"2022","unstructured":"Takahata M, Shimizu T, Yamada S, Yamamoto T, Hasegawa T, Fujita R, Kobayashi H, Endo T, Koike Y, Amizuka N, Todoh M, Okumura J, Kajino T, Iwasaki N (2022) Bone biopsy findings in patients receiving long-term bisphosphonate therapy for glucocorticoid-induced osteoporosis. J Bone Miner Metab 40:613\u2013622. https:\/\/doi.org\/10.1007\/s00774-022-01323-9","journal-title":"J Bone Miner Metab"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05266-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05266-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05266-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:01:11Z","timestamp":1744160471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05266-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5266"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05266-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a retrospective review study with no experimental interventions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This was a retrospective review study with requirement for informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The author declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}